AI Verdict
KALV has stronger fundamentals based on our AI analysis.
KAPA vs KALV Fundamental Comparison
| Metric | KAPA | KALV |
|---|---|---|
| Revenue | N/A | $13.7M |
| Net Income | $-5.4M | $-158.9M |
| Net Margin | N/A | -1,160.0% |
| ROE | -85.9% | -934.8% |
| ROA | -83.3% | -46.7% |
| Current Ratio | 27.07x | 7.22x |
| Debt/Equity | 0.00x | 0.31x |
| EPS | $-0.30 | $-2.97 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KAPA vs KALV: Frequently Asked Questions
Is KAPA or KALV a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KALV has stronger fundamentals. KAPA is rated SELL (85% confidence) while KALV is rated HOLD (45% confidence). This is not investment advice.
How does KAPA compare to KALV fundamentally?
Kairos Pharma, LTD. has ROE of -85.9% vs KalVista Pharmaceuticals, Inc.'s -934.8%. Net margins are N/A vs -1,160.0% respectively.
Which stock pays higher dividends, KAPA or KALV?
KAPA has a dividend yield of N/A or no dividend while KALV has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KAPA or KALV for long term?
For long-term investing, consider that KAPA has SELL rating with 85% confidence, while KALV has HOLD rating with 45% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KAPA vs KALV?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KAPA vs KALV, the AI consensus favors KALV based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.